Pfizer (NYSE:PFE) Stock Falls 1.7% After Analyst Downgrade

Posted by Ethan Ryder on Nov 6th, 2026

Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded down 1.7% during mid-day trading on Friday after DZ Bank downgraded the stock from a buy rating to a hold rating. The stock traded as low as $28.54 and last traded at $29.3810. 48,156,994 shares traded hands during trading, an increase of 21% from the average daily volume of 39,871,961 shares. The stock had previously closed at $29.88.

A number of other brokerages have also commented on PFE. Guggenheim raised their price target on Pfizer from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday. UBS Group lifted their price target on shares of Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Wednesday. JPMorgan Chase & Co. boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 9th. Argus set a $40.00 price objective on shares of Pfizer in a report on Wednesday. Finally, Citigroup upped their price objective on shares of Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Wednesday. Five investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $30.18.

Read Our Latest Stock Analysis on PFE

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Guggenheim raised its price target to $33 from $31 and reiterated a Buy rating, signaling confidence in potential upside. Guggenheim rating
Positive Sentiment: Pfizer’s latest quarterly report beat analyst estimates, and the company raised its 2026 revenue and earnings forecasts. That stronger outlook may help counter concerns about pressure on margins. Pfizer guidance update
Neutral Sentiment: Pfizer updated notices for an ulcerative-colitis treatment-pattern study and a Phase 3 RSV vaccine study in high-risk children. The reports describe ongoing research, but do not provide results that establish a new efficacy or safety finding. Ulcerative colitis study update RSV vaccine study update
Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, adding a cautious analyst signal. Pfizer also lagged as Moderna advanced after reporting an unexpected profit and raising its outlook, potentially drawing attention to competitive comparisons in the vaccine sector. DZ Bank rating Moderna earnings and peer trading

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PFE. Retirement Wealth Solutions LLC boosted its position in shares of Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 509 shares in the last quarter. Keb Asset Management LLC purchased a new stake in shares of Pfizer in the 2nd quarter worth approximately $26,000. Field & Main Bank bought a new position in Pfizer during the 2nd quarter valued at approximately $27,000. Bullseye Investment Management LLC bought a new position in Pfizer during the 2nd quarter valued at approximately $28,000. Finally, Timbuktu Capital Management LLC bought a new position in Pfizer during the 2nd quarter valued at approximately $29,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 1.7%

The stock has a 50 day simple moving average of $28.72 and a 200-day simple moving average of $26.88. The firm has a market cap of $167.46 billion, a PE ratio of 41.97, a PEG ratio of 2.04 and a beta of 0.31. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 0.96.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The business had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the company posted $0.87 earnings per share. The company’s revenue for the quarter was down .4% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 3.02 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s payout ratio is currently 245.71%.